What ChondroFiller does in the hip joint

ChondroFiller is a CE-marked, cell-free Type I collagen scaffold — delivered in the current pathway as an outpatient, ultrasound-guided injection directly into the hip joint. There is no theatre, no general anaesthetic, and no incision: the procedure takes place under local anaesthetic in a clinic setting, with Lincolnshire Hip offering access at Grantham and Sleaford for patients outside London.

Once placed inside the joint, the collagen gel sets rapidly in situ and acts as a physical framework within the cartilage defect. The mechanism is acellular matrix-induced chondrogenesis: the scaffold recruits the patient's own progenitor cells — drawn from the surrounding synovium and the subchondral bone beneath the damaged surface — and supports their differentiation into repair tissue. ChondroFiller does not directly regrow cartilage; it supports the body's own repair processes by providing the structural environment that endogenous repair requires.

The primary clinical target is a focal, full-thickness cartilage defect in the hip — Grade III or IV on standard grading — where a discrete area of damage exists but the surrounding joint surfaces remain reasonably intact. This is distinct from end-stage diffuse osteoarthritis, where cartilage loss is global and a scaffold has considerably less to work with. That distinction, and what it means for patient selection, is explored in a later section.

Harris Hip Score: what a +33-point improvement means in practice

For a patient arriving at clinic with a Harris Hip Score in the low-to-mid 50s — the range that typically reflects constant moderate pain, significant difficulty on stairs, and restricted walking distance — a gain of 33 points moves them into the 80s: the 'good' outcome band. In practice that shift can mean walking without a pronounced limp, returning to low-impact activity, and substantially reduced reliance on pain medication day to day.

The Harris Hip Score is a 0–100 clinician-assessed scale developed by William H. Harris in 1969 and still the dominant outcome instrument for hip surgery and hip preservation. It covers four domains — pain, function, range of movement, and absence of deformity — with pain and function carrying most of the weighting. Published peer-reviewed hip cohorts report a mean improvement of approximately +33 HHS points following ChondroFiller treatment.

Honest caveats apply. The scale has known ceiling effects at the upper end: patients scoring 90 or above cannot demonstrate further gains even if their hip continues to improve. Range-of-movement sub-items also introduce some observer variability, and modern practice increasingly uses patient-reported tools such as WOMAC or the Forgotten Joint Score alongside it. The HHS measures functional outcome — encompassing pain relief, reduced inflammation, and mechanical improvement — not a direct index of how much cartilage tissue has regenerated. Structural repair is assessed separately, using MRI-based tools such as MOCART scoring, which the next section addresses.

MOCART MRI scores of 70–87: what the imaging shows

Scores between 70 and 87 out of 100 on the MOCART scale represent satisfactory-to-good repair tissue — organised fill within the defect, reasonable integration with the surrounding cartilage edges, and an MRI signal approaching that of native tissue, though not the perfect hyaline cartilage of an undamaged joint.

MOCART 2.0 (Magnetic Resonance Observation of Cartilage Repair Tissue) is a structured 0–100 MRI scoring system that grades repair tissue across seven domains: volume fill, integration with adjacent cartilage, surface regularity, signal intensity, bony overgrowth or defect, subchondral changes, and subchondral cysts. Each domain is scored separately and combined into a single figure that allows consistent comparison across patients, clinics, and studies. Its interrater reliability — how consistently two radiologists score the same scan — reaches an ICC of 0.875, meaningfully higher than the original MOCART's 0.759, making it a robust imaging benchmark for cartilage repair research.

One acknowledged limitation is directly relevant here. MOCART 2.0 has been formally validated for the knee and ankle; its application to hip cartilage repair is an extrapolation from those validated versions, and no hip-specific adaptation has been published. Clinicians working in hip preservation note this openly — it is a property of the current evidence base, not a flaw in the imaging itself.

Structural MRI scores and clinical outcomes do not consistently track together. A patient may show a moderate MOCART score yet report marked functional improvement on the Harris Hip Score — and the reverse can also occur. Both data types add meaningful information; neither alone is sufficient to judge how a hip is responding to treatment.

What the published hip evidence actually covers

The single dedicated peer-reviewed study of ChondroFiller in the hip is a prospective cohort published in the Journal of Hip Preservation Surgery in 2021, covering 26 adult patients with femoroacetabular impingement and acetabular cartilage lesions exceeding 2 cm². All were treated by hip arthroscopy with ChondroFiller gel implanted directly into the defect, and follow-up ran from 12 to 60 months. At the three-to-five year review, 17 of the 21 patients who remained available for assessment (81%) achieved good or excellent results, with post-operative MRI showing statistically significant cartilage healing. Two patients progressed to total hip replacement — a clinically important signal, and one the authors report rather than minimise. Patients with pre-existing Tönnis grade 2–3 osteoarthritis fared poorly, establishing advanced OA as a clear contraindication and underlining why patient selection matters as much as the treatment itself.

Every published clinical data point for ChondroFiller in the hip — including that cohort and a 2025 case report of an isolated femoral head lesion in a 32-year-old — comes from the arthroscopic surgical route, not from the intra-articular injection pathway used in outpatient practice today. The injectable form shares the same Type I collagen scaffold and the same biological mechanism of acellular matrix-induced chondrogenesis, but a peer-reviewed injection series specifically for the hip has not yet been published. Real-world injection data are being compiled; they are not yet in the literature. That distinction matters, and any honest account of the evidence should state it plainly.

For wider context: the global ChondroFiller experience now exceeds 19,000 cases across all joints, with the most extensive evidence base in the knee. The aggregated peer-reviewed hip cohorts — not a single RCT — underpin the headline figures of +33 Harris Hip Score points and MOCART regeneration scores of 70–87, both cited from the London Cartilage Clinic's consolidated evidence review. The authors of the 2021 JHPS study themselves call for larger controlled trials; that call reflects the field's current position accurately.

Who is suitable — and who is not

The clearest candidates are patients with a confirmed focal cartilage defect — Grade III or IV on the standard classification — or early-to-moderate joint wear visible on imaging but with sufficient surviving joint space. Femoroacetabular impingement (FAI) is a common co-existing finding in this group, since acetabular cartilage lesions frequently arise in the context of bony impingement — a pattern well-represented in the published hip literature. Patients who have not had adequate relief from conservative measures are typically the ones reaching this point on the pathway.

Where the evidence draws a firm line

The Tönnis classification grades hip osteoarthritis on plain X-ray from 0 (normal) to 3 (severe): grade 2 reflects moderate joint-space narrowing with sclerosis, and grade 3 reflects near-total loss with bony deformity. In the published hip cohort, patients already at Tönnis grade 2–3 before treatment had poor results — the single clearest contraindication signal in the hip-specific literature, not a marginal finding.

Active joint infection is an absolute exclusion regardless of cartilage status. End-stage arthritis — where the articular surface is entirely lost — places a patient outside what this treatment can address.

Before proceeding

A protected-loading period of four to six weeks follows injection, allowing the collagen scaffold to stabilise; patients need to factor this into their plans before booking. A first consultation is most productive when recent cross-sectional hip imaging is available — an MRI is usually the most informative — to confirm defect character, quantify the degree of wear, and establish whether this pathway is appropriate for that particular joint.

Getting assessed in Lincolnshire

This article is published by Lincolnshire Hip, which is part of the MSK Doctors group and provides ChondroFiller injection at outpatient clinics in Grantham and Sleaford. That provenance is worth stating plainly at this point: the clinical summary above draws from peer-reviewed sources, but the service described is one Lincolnshire Hip delivers, and a patient weighing treatment options deserves to know that context rather than encounter it only at the end.

Assessment begins with an initial consultation — no GP referral is required — where recent hip imaging, defect characterisation, and clinical history are reviewed to establish whether ChondroFiller injection is the appropriate pathway for that individual joint. The guide cost is £2,995 per injection; patients should confirm current pricing directly with the clinic before proceeding.

Lincolnshire Hip accepts self-referrals from patients across Lincolnshire and the wider non-London East Midlands catchment for hip assessment at either location.

1. [1] Arthroscopic utilization of ChondroFiller gel for the treatment of hip articular cartilage defects: a cohort study with 12- to 60-month follow-up. (2021). https://doi.org/10.1093/jhps/hnab002 https://doi.org/10.1093/jhps/hnab002
2. [2] The MOCART (Magnetic Resonance Observation of Cartilage Repair Tissue) 2.0 Knee Score and Atlas. (2019). https://doi.org/10.1177/1947603519865308 https://doi.org/10.1177/1947603519865308
3. [3] Reliability of the MOCART 2.0 knee score for different cartilage repair techniques. (2021). https://doi.org/10.1007/s00330-021-07688-1 https://doi.org/10.1007/s00330-021-07688-1